All In Biotech

Drug Trial Radar · NCT07774611

An Open-label Study of SG1827 Combined With Anti-PD-1/PD-L1 Antibody and Bevacizumab in Patients With Advanced Solid Tumors

A Phase 1b/2 Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of SG1827 for Injection in Combination With Anti-PD-1/PD-L1 Antibody and Bevacizumab in Patients With Advanced Malignant Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Sep 18, 2026

Primary completion

Jun 30, 2028

Study completion Dec 31, 2028

Sponsor

Sponsor type
Industry
First posted
Aug 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This multicenter, open-label Phase Ib/II study with dose escalation and expansion in Chinese patients with advanced solid tumors consists of Part A (SG1827 plus anti-PD-1/PD-L1) and Part B (SG1827 plus anti-PD-1/PD-L1 and bevacizumab), both evaluating safety, tolerability, PK/PD, immunogenicity, and antitumor efficacy.

Conditions

  • Advanced Solid Tumors

Interventions

  • SG1827Drug

    Intravenous infusion, once every three weeks

  • anti-PD-1/PD-L1 antibodyDrug

    Intravenous infusion

  • bevacizumabDrug

    Intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AEsTime frame: From first dose until 30 days after last dose of SG1827

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Dongguan People's Hospital

    Dongguan, China · Not yet recruiting

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, China · Not yet recruiting

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China · Not yet recruiting

  • Sun Yat-sen University Cancer Center

    Guanzhou, Guangdong, China · Recruiting

  • The Affiliated Hospital of Chengde Medical University

    Chengde, Hebei, China · Not yet recruiting

  • Harbin Medical University Cencer Hospital

    Haerbin, Heilongjiang, China · Not yet recruiting

  • The First Affiliated Hospital of Henan Medical University

    Xinxiang, Henan, China · Recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Not yet recruiting

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, China · Recruiting

  • Jilin Cancer Hospital

    Changchun, Jilin, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.